16 / 32
Notes:
Page 42
Volume 08
Clinical Pharmacology & Biopharmaceutics
ISSN: 2167-065X
Pharmacology 2019
World Heart Congress 2019
August 19-20, 2019
JOINT EVENT
conferenceseries
.com
August 19-20, 2019 Vienna, Austria
&
7
th
World Heart Congress
24
th
World Congress on
Pharmacology
glycoside. Such therapy was realized with 37 patients having ischemic heart disease and supraventricular paroxysmal
tachyarrhythmias. They were included in the main group of patients.
To control the effectiveness of the combined therapy the monotherapy only using intravenous administration of
allapinin in single dose 40-50 mg was realized with 38 patients having ischemic heart disease and supraventricular
paroxysmal tachyarrhythmias.
The therapy results in the main and in the control group of patients are submitted in the table.
The use of cardiac glycoside increases the antiarrhythmic effect of allapinin. This combined treatment is more
efficient in comparison with the monotherapy with the help of only one preparation (allapinin). Such combined use
of these two medicines contributes to shortening of the time, which is needed for suppression of tachyarrhythmia
paroxysm. After the renew of the normal sinus rhythm the supporting treatment (oral administration of allapinin
and cardiac glycosides) must be administered in the earliest possible period.